TY - JOUR
T1 - Fecal Microbiota Transplantation Across the Lifespan
T2 - Balancing Efficacy, Safety, and Innovation
AU - Gulati, Ajay S.
AU - Nicholson, Maribeth R.
AU - Khoruts, Alexander
AU - Kahn, Stacy A.
N1 - Publisher Copyright:
© 2023 Wolters Kluwer Health. All rights reserved.
PY - 2023/3/1
Y1 - 2023/3/1
N2 - Fecal microbiota transplantation (FMT) is a rapidly growing therapy aimed at reconstituting the dysbiotic microbiota of a patient with the beneficial stool microbiota of a healthy individual. The efficacy rates of FMT are very robust for recurrent Clostridioides difficile infection in both children and adults. Although complications of FMT have been reported, it is generally believed to be a safe procedure. Novel indications for FMT are being studied, with the hope that ultimately it may be useful for a variety of disorders. As this field continues to grow, however, it is necessary to consider efficacy, safety, and innovation across the lifespan. There are unique concerns regarding FMT as it pertains to children, adults, and the elderly. In this review, we seek to update clinicians, researchers, and regulators on how these factors must be balanced across the lifespan as we move forward with this innovative therapy.
AB - Fecal microbiota transplantation (FMT) is a rapidly growing therapy aimed at reconstituting the dysbiotic microbiota of a patient with the beneficial stool microbiota of a healthy individual. The efficacy rates of FMT are very robust for recurrent Clostridioides difficile infection in both children and adults. Although complications of FMT have been reported, it is generally believed to be a safe procedure. Novel indications for FMT are being studied, with the hope that ultimately it may be useful for a variety of disorders. As this field continues to grow, however, it is necessary to consider efficacy, safety, and innovation across the lifespan. There are unique concerns regarding FMT as it pertains to children, adults, and the elderly. In this review, we seek to update clinicians, researchers, and regulators on how these factors must be balanced across the lifespan as we move forward with this innovative therapy.
KW - Clostridioides difficile
KW - biotherapeutics
KW - fecal microbiota transplant
KW - lifespan
KW - microbiota
UR - http://www.scopus.com/inward/record.url?scp=85148947140&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85148947140&partnerID=8YFLogxK
U2 - 10.14309/ajg.0000000000002167
DO - 10.14309/ajg.0000000000002167
M3 - Review article
C2 - 36580630
AN - SCOPUS:85148947140
SN - 0002-9270
VL - 118
SP - 435
EP - 439
JO - American Journal of Gastroenterology
JF - American Journal of Gastroenterology
IS - 3
ER -